Tokyo Tape
Sign in
← PeptiDream

Quarterly report · Q2

4587.TEDINET S100S6V5
Period2023-01-01 → 2023-06-30
Filed2023-11-09
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed

Amends S100RNSH.

Key figures · 62
MetricValuePeriodScopeSource row
Revenue¥9.4bn2023-01-01 → 2023-06-30Cons.Revenue IFRS
Revenue¥4.5bn2023-04-01 → 2023-06-30dCons.Revenue IFRS
Revenue¥26.9bn2022-01-01 → 2022-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥5.0bn2022-01-01 → 2022-06-30Cons.Revenue IFRS
Revenue¥4.6bn2022-04-01 → 2022-06-30dCons.Revenue IFRS
Operating income−¥986m2023-01-01 → 2023-06-30Cons.Operating profit loss IFRS
Operating income−¥720m2023-04-01 → 2023-06-30dCons.Operating profit loss IFRS
Operating income−¥1.7bn2022-01-01 → 2022-06-30Cons.Operating profit loss IFRS
Operating income−¥499m2022-04-01 → 2022-06-30dCons.Operating profit loss IFRS
Profit before tax−¥1.1bn2023-01-01 → 2023-06-30Cons.Profit loss before tax IFRS
Profit before tax−¥711m2023-04-01 → 2023-06-30dCons.Profit loss before tax IFRS
Profit before tax¥6.7bn2022-01-01 → 2022-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax−¥1.6bn2022-01-01 → 2022-06-30Cons.Profit loss before tax IFRS
Profit before tax−¥467m2022-04-01 → 2022-06-30dCons.Profit loss before tax IFRS
Net income (owners)−¥729m2023-01-01 → 2023-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥480m2023-04-01 → 2023-06-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥7.6bn2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)−¥1.1bn2022-01-01 → 2022-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥303m2022-04-01 → 2022-06-30dCons.Profit loss attributable to owners of parent IFRS
Net income−¥729m2023-01-01 → 2023-06-30Cons.Profit loss IFRS
Net income−¥480m2023-04-01 → 2023-06-30dCons.Profit loss IFRS
Net income¥7.6bn2022-01-01 → 2022-12-31Cons.Profit loss IFRS (5-year summary)
Net income−¥1.1bn2022-01-01 → 2022-06-30Cons.Profit loss IFRS
Net income−¥303m2022-04-01 → 2022-06-30dCons.Profit loss IFRS
Total assets¥57.7bnat 2023-06-30Cons.Assets IFRS
Total assets¥63.9bnat 2022-12-31Cons.Assets IFRS
Total assets¥52.4bnat 2022-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥26.7bnat 2023-06-30Cons.Liabilities IFRS
Total liabilities¥31.8bnat 2022-12-31Cons.Liabilities IFRS
Net assets / equity¥31.0bnat 2023-06-30Cons.Equity IFRS
Net assets / equity¥32.0bnat 2022-12-31Cons.Equity IFRS
Net assets / equity¥24.7bnat 2022-06-30Cons.Equity IFRS
Net assets / equity¥25.4bnat 2021-12-31dCons.Equity IFRS
Equity (owners)¥31.0bnat 2023-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥32.0bnat 2022-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥24.7bnat 2022-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥11.2bnat 2023-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥5.2bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥6.4bnat 2022-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.7bnat 2021-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥8.8bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow−¥83m2022-01-01 → 2022-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow−¥493m2022-01-01 → 2022-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥798m2023-01-01 → 2023-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥27.4bn2022-01-01 → 2022-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥26.7bn2022-01-01 → 2022-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥2.3bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥20.8bn2022-01-01 → 2022-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥21.6bn2022-01-01 → 2022-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-5.622023-01-01 → 2023-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥-3.72023-04-01 → 2023-06-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥58.192022-01-01 → 2022-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥-8.722022-01-01 → 2022-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥-2.332022-04-01 → 2022-06-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥-5.622023-01-01 → 2023-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥-3.72023-04-01 → 2023-06-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥58.142022-01-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥-8.722022-01-01 → 2022-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥-2.332022-04-01 → 2022-06-30dCons.Diluted earnings loss per share IFRS
Equity ratio53.8%at 2023-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio50.2%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio47.0%at 2022-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 22
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-06-30−¥30m
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-06-30−¥30m
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2023-01-01 → 2023-06-30¥1.5bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2023-01-01 → 2023-06-30¥1.5bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2023-01-01 → 2023-06-30−¥1.2bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2023-01-01 → 2023-06-30¥8.0bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2023-01-01 → 2023-06-30¥8.0bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2023-01-01 → 2023-06-30¥30m
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2023-01-01 → 2023-06-30¥228m
—segment totalrevenue2023-01-01 → 2023-06-30¥9.5bn
—segment totalrevenue external2023-01-01 → 2023-06-30¥9.4bn
—segment totalrevenue intersegment2023-01-01 → 2023-06-30¥30m
—segment totalsegment profit2023-01-01 → 2023-06-30−¥941m
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2022-01-01 → 2022-06-30¥1.1bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2022-01-01 → 2022-06-30¥1.1bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2022-01-01 → 2022-06-30−¥1.4bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2022-01-01 → 2022-06-30¥3.9bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2022-01-01 → 2022-06-30¥3.9bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2022-01-01 → 2022-06-30¥114m
—segment totalrevenue2022-01-01 → 2022-06-30¥5.0bn
—segment totalrevenue external2022-01-01 → 2022-06-30¥5.0bn
—segment totalsegment profit2022-01-01 → 2022-06-30−¥1.3bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 634
ItemContextValueUnit
Independent auditors report consolidated (text)FilingDateInstantText · Plus
Audit firm1 consolidatedFilingDateInstant
Original text (Japanese)有限責任 あずさ監査法人
Cpa1 audit firm1 consolidatedFilingDateInstant
Original text (Japanese)上　野　　直　樹
Cpa2 audit firm1 consolidatedFilingDateInstant
Original text (Japanese)猪　俣　　雅　弘
Number of submissionFilingDateInstant2
Revenue IFRS (5-year summary)Prior1YTDDuration5024397000JPY
Revenue IFRS (5-year summary)CurrentYTDDuration9426049000JPY
Revenue IFRS (5-year summary)Prior1YearDuration26852430000JPY
Revenue IFRS (5-year summary)Prior1QuarterDuration4604870000JPY
Revenue IFRS (5-year summary)CurrentQuarterDuration4462579000JPY
Profit loss before tax IFRS (5-year summary)Prior1YTDDuration-1590972000JPY
Profit loss before tax IFRS (5-year summary)CurrentYTDDuration-1110932000JPY
Profit loss before tax IFRS (5-year summary)Prior1YearDuration6653325000JPY
Profit loss attributable to owners of parent IFRS (5-year summary)Prior1YTDDuration-1132251000JPY
Profit loss attributable to owners of parent IFRS (5-year summary)CurrentYTDDuration-729014000JPY
Profit loss attributable to owners of parent IFRS (5-year summary)Prior1YearDuration7554358000JPY
Profit loss attributable to owners of parent IFRS (5-year summary)Prior1QuarterDuration-302955000JPY
Profit loss attributable to owners of parent IFRS (5-year summary)CurrentQuarterDuration-480212000JPY
Profit loss IFRS (5-year summary)Prior1YTDDuration-1132251000JPY
Profit loss IFRS (5-year summary)CurrentYTDDuration-729014000JPY
Profit loss IFRS (5-year summary)Prior1YearDuration7554358000JPY
Comprehensive income attributable to owners of parent IFRS (5-year summary)Prior1YTDDuration-699080000JPY
Comprehensive income attributable to owners of parent IFRS (5-year summary)CurrentYTDDuration-516755000JPY
Comprehensive income attributable to owners of parent IFRS (5-year summary)Prior1YearDuration6606348000JPY
Comprehensive income IFRS (5-year summary)Prior1YTDDuration-699080000JPY
Comprehensive income IFRS (5-year summary)CurrentYTDDuration-516755000JPY
Comprehensive income IFRS (5-year summary)Prior1YearDuration6606348000JPY
Equity attributable to owners of parent IFRS (5-year summary)Prior1QuarterInstant24663182000JPY
Equity attributable to owners of parent IFRS (5-year summary)CurrentQuarterInstant31020624000JPY
Equity attributable to owners of parent IFRS (5-year summary)Prior1YearInstant32041465000JPY
Total assets IFRS (5-year summary)Prior1QuarterInstant52425540000JPY
Total assets IFRS (5-year summary)CurrentQuarterInstant57704497000JPY
Total assets IFRS (5-year summary)Prior1YearInstant63865200000JPY
Basic earnings loss per share IFRS (5-year summary)Prior1YTDDuration-8.72
Basic earnings loss per share IFRS (5-year summary)CurrentYTDDuration-5.62
Basic earnings loss per share IFRS (5-year summary)Prior1YearDuration58.19
Basic earnings loss per share IFRS (5-year summary)Prior1QuarterDuration-2.33
Basic earnings loss per share IFRS (5-year summary)CurrentQuarterDuration-3.70
Diluted earnings loss per share IFRS (5-year summary)Prior1YTDDuration-8.72
Diluted earnings loss per share IFRS (5-year summary)CurrentYTDDuration-5.62
Diluted earnings loss per share IFRS (5-year summary)Prior1YearDuration58.14
Ratio of owners equity to gross assets IFRS (5-year summary)Prior1QuarterInstant0.470
Ratio of owners equity to gross assets IFRS (5-year summary)CurrentQuarterInstant0.538
Ratio of owners equity to gross assets IFRS (5-year summary)Prior1YearInstant0.502
Cash flows from used in operating activities IFRS (5-year summary)Prior1YTDDuration-492704000JPY
Cash flows from used in operating activities IFRS (5-year summary)CurrentYTDDuration8769521000JPY
Cash flows from used in operating activities IFRS (5-year summary)Prior1YearDuration-82929000JPY
Cash flows from used in investing activities IFRS (5-year summary)Prior1YTDDuration-26679922000JPY
Cash flows from used in investing activities IFRS (5-year summary)CurrentYTDDuration-797543000JPY
Cash flows from used in investing activities IFRS (5-year summary)Prior1YearDuration-27377217000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2022-12-31pass rounding
balance sheet identityconsolidated 2023-06-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-06-30pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-06-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2022-12-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass